New Hope for Heart Failure Patients: Real-Time Breathing Monitoring

Every day we breathe about 20,000 times, almost without noticing. Although this is one of the basic life functions, from a medical perspective it presents a rather unexpected challenge : although we can measure pulse, blood pressure, and body temperature, there is no available way to measure breathing quality in real time. "It's amazing to discover that there is still no quantitative respiratory monitoring in daily life," says Dr. Gideon Stein, CEO of Resmetrix Medical. "As physicians, we need to rely on patient reports rather than quantitative and objective measurement, which makes effective intervention difficult." The reason is not the absence of respiratory parameters, but the difficulty in measuring them in daily life.

With a breakthrough development, the Resmetrix technology offers the ability to measure these respiratory parameters easily and continuously, opening the door to a significant leap in medical treatment that will profoundly affect the quality of life of tens of millions of patients worldwide.

Early detection of changes in breathing patterns
More than 200 million people worldwide suffer from diseases with chronic respiratory symptoms but do not receive continuous respiratory monitoring that could improve their treatment outcomes and quality of life. "We count breaths, but not their varying volume. Knowing both the number of breaths and their volume allows us to know the air consumption over time. Today, only in ventilated patients can air consumption be measured continuously," explains Dr. Stein.

What makes your technology a revolutionary solution in respiratory monitoring?
"The technology can measure minute changes in chest cavity volume, with a precision level of 20 micrometers. This enables measurement of spontaneous breathing volumes, identification of changes in breathing volumes and patterns, and quantitative characterization of respiratory symptoms. Additionally, our solution guides the patient continuously in daily life, and is not limited to laboratory or clinic use." At the heart of the system is an innovative sensor protected by international patents.

What is the advantage of such monitoring for the healthcare system?
"There is a saying that 'you cannot manage what you cannot measure,' and this is especially true in medicine. The precision and ability to measure continuous data allow for earlier identification of changes in breathing patterns, real-time alerts about breathing changes and deterioration, making it possible to adapt treatment in a personalized and effective way. Implementation of the solution is expected not only to improve patients' lives but also to reduce the number of doctor visits, prevent unnecessary hospitalizations, and enable patients and the healthcare system to save costs."

Non-invasive respiratory monitoring
To validate the technology's effectiveness, clinical trials demonstrated a strong correlation between Resmetrix s' system and traditional spirometry in measuring spontaneous breathing volumes. . "The trials also showed that the system is suitable for monitoring cases of asthma— tracking respiratory deterioration , and improvement following treatment," says Dr. Stein.The technology developed by Resmetrix is applicable to a wide range of respiratory diseases. The company chose to focus initially on heart failure, a market with significant medical and economic potential. In the US alone, about 6 million people live with the disease, and more than a million of them are hospitalized annually because of respiratory deterioration."Respiratory deterioration in heart failure patients is a key symptom that causes patients to seek me dical attention," Dr. Stein explain. "About 25% of discharged heart failure patients get readmitted to the hospital within a month, and 50% of them within six months, after discharge. The recurring hospitalizations increase the patients' risk of critical disability and death, and significantly reduce their quality of life. The overall economic impact of this disease on the healthcare system is significant, with a total annual expenditure in the US of about 30 billion dollars."

There are currently other solutions in the market that haven't gained traction. How do you explain this?
"The CardioMEMS™ HF system is the first and only device approved by the FDA for monitoring heart failure outside the hospital. It provides doctors with additional quantitative parameter, changes in pulmonary artery (PA) pressure

, enabling proactive management of heart failure and reduction of repeat hospitalizations. Nevertheless, most heart failure patients in the US are not monitored by this system because it involves an invasive procedure and its significant costs. Additionally, pulmonary artery pressure is a sign but does not constitute a measurement of the respiratory symptom itself, which the patient feels and consequently seeks medical treatment. By contrast, the solution that Resmetrix is developing measures the respiratory symptom itself directly and quantitatively. It is non-invasive, accessible, and significantly lower in cost."

Behind Resmetrix stand three serial entrepreneurs: Dr. Zvi Reznik, PhD in electrical engineering, with a rich experience in algorithm development and systems engineering, one of the founders of Amimon; Prof. Ari Derowe, Head of Pediatric ENT at the Sourasky Medical Center, inventor of medical devices such as InStent, InFluENT (AIRvance™ System Medtronic), and ByPass; and Dr. Gideon Stein, an ENT specialist with 25 years of experience in drug development and leading startups in the medical devices field. Together, the three created a strong foundation for developing innovative technology that combines advanced science with practical applications.

Currently, Resmetrix is focusing on expanding its system capabilities and establishing collaborations with key players in the healthcare system and several telemedicine companies, aspiring to lead a global revolution in respiratory monitoring.

Where do you aim to take the field of respiratory monitoring in the coming years?
"Resmetrix is at the forefront of this revolution," says Dr. Stein. "Our vision is to make continuous breathing data accessible to every patient worldwide, transforming respiratory monitoring from subjective observation to measurable, objective, and accurate information. By doing so, we aim to enable better medical care and improve millions of lives."

Resmetrix Medical
Year of establishment: 2017.
Founders: Dr. Zvi Reznik, Prof. Ari Derowe, Dr. Gideon Stein. Field of activity: Medical technology for continuous respiratory monitoring.
Leading motto: "To transform respiratory monitoring from a subjective symptom to measurable, objective, accurate, and accessible information"

In collaboration with Resmetrix Medical